From: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
Mean cost per treated patient
Parameter
Prophylaxis
Non prophylaxis
Difference
- BPD
6,517.26
6,003.79
513.47
- < 33 weeks
5,819.65
4,429.13
1,390.52
- 33–35 weeks
6,199.79
3,979.70
2,220.09
Total
6,244.20
4,867.70
1,376.50